Aridis Pharmaceuticals Q3 2023 Earnings Results & Report

Aridis Pharmaceuticals EPS Results

• Actual EPS: -$0.02
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A
• EPS Beat Rate: 2 of last 8 quarters

Aridis Pharmaceuticals Revenue Results

• Actual Revenue: $0.42 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Aridis Pharmaceuticals (NASDAQ:ARDS) was a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for serious infectious diseases. The company’s approach centered on fully human monoclonal antibodies designed to target specific bacterial pathogens and their disease-causing mechanisms, with the goal of providing alternatives or complements to traditional antibiotics.

Aridis’ principal development programs included AR-301, also known as suvratoxumab, an investigational monoclonal antibody directed against Pseudomonas aeruginosa alpha toxin. The program was evaluated for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. The company also pursued additional antibody programs aimed at other bacterial infections, including candidates targeting pathogens associated with serious hospital and respiratory infections.

Founded in 2003 and based in San Jose, California, Aridis conducted its research and clinical development activities primarily through collaborations and clinical studies involving patients in the United States and other regions. The company was led by founder and Chief Executive Officer Vu Truong, Ph.D. Aridis was a development-stage company, and its programs remained investigational rather than commercially approved products.